Menu

Re-evaluation of the cardioprotective effects of cannabinoids against ischemia-reperfusion injury according to the IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria

Abstract

Ischemic heart disease, associated with high morbidity and mortality, represents a major challenge for the development of drug-based strategies to improve its prognosis. Results of pre-clinical studies suggest that agonists of cannabinoid CB2 receptors and multitarget cannabidiol might be potential cardioprotective strategies against ischemia-reperfusion injury. The aim of our study was to re-evaluate the cardioprotective effects of cannabinoids against ischemia-reperfusion injury according to the IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria published recently by the European Union (EU) CARDIOPROTECTION COST ACTION. To meet the minimum criteria of those guidelines, experiments should be performed (i) on healthy small animals subjected to ischemia with reperfusion lasting for at least 2 hours and (ii) confirmed in small animals with comorbidities and co-medications and (iii) in large animals. Our analysis revealed that the publications regarding cardioprotective effects of CB2 receptor agonists and cannabidiol did not meet all three strict steps of IMPACT. Thus, additional experiments are needed to confirm the cardioprotective activities of (endo)cannabinoids mainly on small animals with comorbidities and on large animals. Moreover, our publication underlines the significance of the IMPACT criteria for a proper planning of preclinical experiments regarding cardiac ischemia-reperfusion injury.

Article type: Review Article

Keywords: Cannabinoids, Cannabinoid receptor, Cannabidiol, Myocardial ischemia-reperfusion injury, Myocardial infarction, IMproving Preclinical assessment of Cardioprotective therapies (IMPACT)

Authors: Anna Pędzińska-Betiuk, Eberhard Schlicker, Jolanta Weresa, Barbara Malinowska

Affiliations: Department of Experimental Physiology and Pathophysiology, Medical University of Bialystok, Bialystok, Poland; Department of Pharmacology and Toxicology, University of Bonn, Bonn, Germany

License: Copyright © 2024 Pędzińska-Betiuk, Schlicker, Weresa and Malinowska. CC BY 4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Article links: DOI: 10.3389/fphar.2024.1382995  |  PubMed: 38873412  |  PMC: PMC11170160

Relevance: Moderate: mentioned 3+ times in text

Full text: PDF (2.2 MB)

References

  1. S. Atalay, I. Jarocka-Karpowicz, E. Skrzydlewska. Antioxidative and anti-inflammatory properties of cannabidiol.. Antioxidants (Basel), 2019. [DOI | PubMed]
  2. M. Banaszkiewicz, P. Tarwacka, A. Krzywonos-Zawadzka, A. Olejnik, R. Laprairie, A. Noszczyk-Nowak. Δ9-Tetrahydrocannabinol (Δ9-THC) improves ischemia/reperfusion heart dysfunction and might serve as a cardioprotective agent in the future treatment.. Front. Biosci. Landmark Ed., 2022. [DOI | PubMed]
  3. M. V. Basalay, D. M. Yellon, S. M. Davidson. Targeting myocardial ischaemic injury in the absence of reperfusion.. Basic Res. Cardiol., 2020. [DOI | PubMed]
  4. R. Bolli. CAESAR’s legacy: a new era of rigor in preclinical studies of cardioprotection.. Basic Res. Cardiol., 2021. [DOI | PubMed]
  5. A. Bonz, M. Laser, S. Küllmer, S. Kniesch, J. Babin-Ebell, V. Popp. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle.. J. Cardiovasc. Pharmacol., 2003. [DOI | PubMed]
  6. J. F. Bouchard, P. Lépicier, D. Lamontagne. Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart.. Life Sci., 2003. [DOI | PubMed]
  7. L. C. Boyette, B. Manna. Physiology, myocardial oxygen demand,” in. StatPearls (, 2023
  8. M. Bryk, K. Starowicz. Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB2 receptor in the arthritis progression and pain: an updated review.. Pharmacol. Rep., 2021. [DOI | PubMed]
  9. L. M. Buja. Pathobiology of myocardial ischemia and reperfusion injury: models, modes, molecular mechanisms, modulation, and clinical applications.. Cardiol. Rev., 2023. [DOI | PubMed]
  10. S. Comità, C. Rubeo, M. Giordano, C. Penna, P. Pagliaro. Pathways for cardioprotection in perspective: focus on remote conditioning and extracellular vesicles.. Biol. (Basel), 2023. [DOI]
  11. S. M. Davidson, P. Ferdinandy, I. Andreadou, H. E. Bøtker, G. Heusch, B. Ibáñez. Multitarget strategies to reduce myocardial ischemia/reperfusion injury: JACC review topic of the week.. J. Am. Coll. Cardiol., 2019. [DOI | PubMed]
  12. N. Defer, J. Wan, R. Souktani, B. Escoubet, M. Perier, P. Caramelle. The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy.. FASEB J., 2009. [DOI | PubMed]
  13. R. M. Deng, J. Zhou. The role of PI3K/AKT signaling pathway in myocardial ischemia-reperfusion injury.. Int. Immunopharmacol., 2023. [DOI | PubMed]
  14. C. Di Filippo, F. Rossi, S. Rossi, M. D’Amico. Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN.. J. Leukoc. Biol., 2004. [DOI | PubMed]
  15. G. D. Duerr, J. C. Heinemann, C. Gestrich, T. Heuft, T. Klaas, K. Keppel. Impaired border zone formation and adverse remodeling after reperfused myocardial infarction in cannabinoid CB2 receptor deficient mice.. Life Sci., 2015. [DOI | PubMed]
  16. G. D. Duerr, J. C. Heinemann, G. Suchan, E. Kolobara, D. Wenzel, C. Geisen. The endocannabinoid-CB2 receptor axis protects the ischemic heart at the early stage of cardiomyopathy.. Basic Res. Cardiol., 2014. [DOI | PubMed]
  17. R. Durst, H. Danenberg, R. Gallily, R. Mechoulam, K. Meir, E. Grad. Cannabidiol, a nonpsychoactive cannabis constituent, protects against myocardial ischemic reperfusion injury.. Am. J. Physiol. Heart Circ. Physiol., 2007. [DOI | PubMed]
  18. Y. Feng, F. Chen, T. Yin, Q. Xia, Y. Liu, G. Huang. Pharmacologic effects of cannabidiol on acute reperfused myocardial infarction in rabbits: evaluated with 3.0T cardiac magnetic resonance imaging and histopathology.. J. Cardiovasc. Pharmacol., 2015. [DOI | PubMed]
  19. P. Ferdinandy, I. Andreadou, G. F. Baxter, H. E. Bøtker, S. M. Davidson, D. Dobrev. Interaction of cardiovascular nonmodifiable risk factors, comorbidities and comedications with ischemia/reperfusion injury and cardioprotection by pharmacological treatments and ischemic conditioning.. Pharmacol. Rev., 2023. [DOI | PubMed]
  20. A. Franco-Vadillo, M. Toledo-Blass, Z. Rivera-Herrera, G. Guevara-Balcazar, O. Orihuela-Rodriguez, J. A. Morales-Carmona. Cannabidiol-mediated RISK PI3K/AKT and MAPK/ERK pathways decreasing reperfusion myocardial damage.. Pharmacol. Res. Perspect., 2021. [DOI | PubMed]
  21. H. T. Garberg, R. Solberg, J. Barlinn, J. Martinez-Orgado, E. M. Løberg, O. D. Saugstad. High-dose cannabidiol induced hypotension after global hypoxia-ischemia in piglets.. Neonatology, 2017. [DOI | PubMed]
  22. G. Giannakopoulos, S. Noble. Should we be using upstream Beta-blocker therapy for acute myocardial infarction?. Curr. Cardiol. Rep., 2021. [DOI | PubMed]
  23. C. M. Gibson. Time is myocardium and time is outcomes.. Circulation, 2001. [DOI | PubMed]
  24. A. Gimelli, D. Rovai. Myocardium at risk: reasons and methods for measuring the extent.. J. Nucl. Cardiol., 2013. [DOI | PubMed]
  25. E. Gonca, F. Darıcı. The effect of cannabidiol on ischemia/reperfusion-induced ventricular arrhythmias: the role of adenosine A1 receptors.. J. Cardiovasc. Pharmacol. Ther., 2015. [DOI | PubMed]
  26. C. González, E. Herradón, R. Abalo, G. Vera, B. G. Pérez-Nievas, J. C. Leza. Cannabinoid/agonist WIN 55,212-2 reduces cardiac ischaemia–reperfusion injury in Zucker diabetic fatty rats: role of CB2 receptors and iNOS/eNOS.. Diabetes Metab. Res. Rev., 2011. [DOI | PubMed]
  27. A. S. Gorbunov, L. N. Maslov, S. Y. Tsibulnikov, I. G. Khaliulin, A. V. Tsepokina, M. V. Khutornaya. CB-receptor agonist HU-210 mimics the postconditioning phenomenon of isolated heart.. Bull. Exp. Biol. Med., 2016. [DOI | PubMed]
  28. R. Guerrero-Alba, P. Barragán-Iglesias, A. González-Hernández, E. E. Valdez-Moráles, V. Granados-Soto, M. Condés-Lara. Some prospective alternatives for treating pain: the endocannabinoid system and its putative receptors GPR18 and GPR55.. Front. Pharmacol., 2019. [DOI | PubMed]
  29. A. R. Hajrasouliha, S. Tavakoli, M. Ghasemi, P. Jabehdar-Maralani, H. Sadeghipour, F. Ebrahimi. Endogenous cannabinoids contribute to remote ischemic preconditioning via cannabinoid CB2 receptors in the rat heart.. Eur. J. Pharmacol., 2008. [DOI | PubMed]
  30. J. C. Heinemann, G. D. Duerr, K. Keppel, M. Breitbach, B. K. Fleischmann, A. Zimmer. CB2 receptor-mediated effects of pro-inflammatory macrophages influence survival of cardiomyocytes.. Life Sci., 2015. [DOI | PubMed]
  31. G. Heusch. Coronary microvascular obstruction: the new frontier in cardioprotection.. Basic Res. Cardiol., 2019. [DOI | PubMed]
  32. G. Heusch. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective.. Nat. Rev. Cardiol., 2020. [DOI | PubMed]
  33. G. Heusch. Cardioprotection and its translation: a need for new paradigms? Or for new pragmatism? An opinionated retro- and perspective.. J. Cardiovasc. Pharmacol. Ther., 2023. [DOI | PubMed]
  34. Y. Hu, Y. Tao, J. Hu. Cannabinoid receptor 2 deletion deteriorates myocardial infarction through the down-regulation of AMPK-mTOR-p70S6K signaling-mediated autophagy.. Biosci. Rep., 2019. [DOI | PubMed]
  35. Z. Hu, S. Mu, L. Zhao, Z. Dou, P. Wang, J. Zhang. Regulation of the CB1R/AMPK/PGC-1α signaling pathway in mitochondria of mouse hearts and cardiomyocytes with chronic intermittent hypoxia.. Sleep. Breath., 2023. [DOI | PubMed]
  36. C. Humeres, H. Venugopal, N. G. Frangogiannis. Smad-dependent pathways in the infarcted and failing heart.. Curr. Opin. Pharmacol., 2022. [DOI | PubMed]
  37. E. J. Ishac, L. Jiang, K. D. Lake, K. Varga, M. E. Abood, G. Kunos. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves.. Br. J. Pharmacol., 1996. [DOI | PubMed]
  38. J. Jehle, H. Goerich, L. Bindila, B. Lutz, G. Nickenig, V. Tiyerili. Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome.. PLoS One, 2019. [DOI | PubMed]
  39. M. Joyeux, C. Arnaud, D. Godin-Ribuot, P. Demenge, D. Lamontagne, C. Ribuot. Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts.. Cardiovasc. Res., 2002. [DOI | PubMed]
  40. T. Kalogeris, C. P. Baines, M. Krenz, R. J. Korthuis. Ischemia/reperfusion.. Compr. Physiol., 2016. [DOI | PubMed]
  41. A. Kicman, M. Toczek. The effects of cannabidiol, a non-intoxicating compound of cannabis, on the cardiovascular system in health and disease.. Int. J. Mol. Sci., 2020. [DOI | PubMed]
  42. J. Kim, D. Kang, H. Park, M. Kang, T. K. Park, J. M. Lee. Long-term β-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study.. Eur. Heart J., 2020. [DOI | PubMed]
  43. T. Kong, M. Liu, B. Ji, B. Bai, B. Cheng, C. Wang. Role of the extracellular signal-regulated kinase 1/2 signaling pathway in ischemia-reperfusion injury.. Front. Physiol., 2019. [DOI | PubMed]
  44. A. V. Krylatov, R. V. Uzhachenko, L. N. Maslov, N. A. Bernatskaya, A. Makriyannis, R. Mechoulam. Endogenous cannabinoids improve myocardial resistance to arrhythmogenic effects of coronary occlusion and reperfusion: a possible mechanism.. Bull. Exp. Biol. Med., 2002. [DOI | PubMed]
  45. C. Lagneux, D. Lamontagne. Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide.. Br. J. Pharmacol., 2001. [DOI | PubMed]
  46. D. Lamontagne, P. Lépicier, C. Lagneux, J. F. Bouchard. The endogenous cardiac cannabinoid system: a new protective mechanism against myocardial ischemia.. Arch. Mal. Coeur. Vaiss., 2006. [PubMed]
  47. J. A. Lang, J. Kim. Remote ischaemic preconditioning – translating cardiovascular benefits to humans.. J. Physiol., 2022. [DOI | PubMed]
  48. S. Lecour, I. Andreadou, H. E. Bøtker, S. M. Davidson, G. Heusch, M. Ruiz-Meana. Improving preclinical assessment of cardioprotective therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action.. Basic Res. Cardiol., 2021. [DOI | PubMed]
  49. Z. J. Leinen, R. Mohan, L. S. Premadasa, A. Acharya, M. Mohan, S. N. Byrareddy. Therapeutic potential of cannabis: a comprehensive review of current and future applications.. Biomedicines, 2023. [DOI | PubMed]
  50. P. Lépicier, A. Bibeau-Poirier, C. Lagneux, M. J. Servant, D. Lamontagne. Signaling pathways involved in the cardioprotective effects of cannabinoids.. J. Pharmacol. Sci., 2006. [DOI | PubMed]
  51. P. Lépicier, J. F. Bouchard, C. Lagneux, D. Lamontagne. Endocannabinoids protect the rat isolated heart against ischaemia.. Br. J. Pharmacol., 2003. [DOI | PubMed]
  52. P. Lépicier, C. Lagneux, M. G. Sirois, D. Lamontagne. Endothelial CB1-receptors limit infarct size through NO formation in rat isolated hearts.. Life Sci., 2007. [DOI | PubMed]
  53. Q. Li, H. C. Guo, L. N. Maslov, X. W. Qiao, J. J. Zhou, Y. Zhang. Mitochondrial permeability transition pore plays a role in the cardioprotection of CB2 receptor against ischemia-reperfusion injury.. Can. J. Physiol. Pharmacol., 2014. [DOI | PubMed]
  54. Q. Li, M. Shi, B. Li. Anandamide enhances expression of heat shock protein 72 to protect against ischemia-reperfusion injury in rat heart.. J. Physiol. Sci., 2013a. [DOI | PubMed]
  55. Q. Li, F. Wang, Y. M. Zhang, J. J. Zhou, Y. Zhang. Activation of cannabinoid type 2 receptor by JWH133 protects heart against ischemia/reperfusion-induced apoptosis.. Cell. Physiol. biochem., 2013b. [DOI | PubMed]
  56. X. Li, D. Han, Z. Tian, B. Gao, M. Fan, C. Li. Activation of cannabinoid receptor type II by AM1241 ameliorates myocardial fibrosis via nrf2-mediated inhibition of TGF-β1/smad3 pathway in myocardial infarction mice.. Cell. Physiol. biochem., 2016. [DOI | PubMed]
  57. Y. Liao, J. Bin, T. Luo, H. Zhao, C. Ledent, M. Asakura. CB1 cannabinoid receptor deficiency promotes cardiac remodeling induced by pressure overload in mice.. Int. J. Cardiol., 2013. [DOI | PubMed]
  58. S. Y. Lim, S. M. Davidson, D. M. Yellon, C. C. Smith. The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction.. Basic Res. Cardiol., 2009. [DOI | PubMed]
  59. M. L. Lindsey, K. R. Brunt, J. A. Kirk, P. Kleinbongard, J. W. Calvert, L. E. de Castro Brás. Guidelines for in vivo mouse models of myocardial infarction.. Am. J. Physiol. Heart Circ. Physiol., 2021. [DOI | PubMed]
  60. W. Liu, C. Chen, X. Gu, L. Zhang, X. Mao, Z. Chen. AM1241 alleviates myocardial ischemia-reperfusion injury in rats by enhancing Pink1/Parkin-mediated autophagy.. Life Sci., 2021. [DOI | PubMed]
  61. Y. Liu, L. Li, Z. Wang, J. Zhang, Z. Zhou. Myocardial ischemia-reperfusion injury; molecular mechanisms and prevention.. Microvasc. Res., 2023. [DOI | PubMed]
  62. M. Maccarrone, V. Di Marzo, J. Gertsch, U. Grether, A. C. Howlett, T. Hua. Goods and bads of the endocannabinoid system as a therapeutic target: lessons learned after 30 years.. Pharmacol. Rev., 2023. [DOI | PubMed]
  63. N. Maeda, T. Osanai, M. Kushibiki, T. Fujiwara, Y. Tamura, S. Oowada. Increased serum anandamide level at ruptured plaque site in patients with acute myocardial infarction.. Fundam. Clin. Pharmacol., 2009. [DOI | PubMed]
  64. L. N. Maslov, I. Khaliulin, Y. Zhang, A. V. Krylatov, N. V. Naryzhnaya, R. Mechoulam. Prospects for creation of cardioprotective drugs based on cannabinoid receptor agonists.. J. Cardiovasc. Pharmacol. Ther., 2016. [DOI | PubMed]
  65. L. N. Maslov, O. V. Lasukova, A. V. Krylatov, L. O. Hanus, R. Pertwee, I. I. Ivanchuk. Role of cannabinoid receptors in the regulation of cardiac contractility during ischemia/reperfusion.. Bull. Exp. Biol. Med., 2006. [DOI | PubMed]
  66. L. N. Maslov, O. V. Lasukova, A. V. Krylatov, R. V. Uzhachenko, R. Pertwee. Selective cannabinoid receptor agonist HU-210 decreases pump function of isolated perfused heart: role of cAMP and cGMP.. Bull. Exp. Biol. Med., 2004. [DOI | PubMed]
  67. L. N. Maslov, N. V. Naryzhnaya, N. S. Voronkov, B. K. Kurbatov, I. A. Derkachev, V. V. Ryabov. The role of β-adrenergic receptors in the regulation of cardiac tolerance to ischemia/reperfusion. Why do β-adrenergic receptor agonists and antagonists protect the heart?. Fundam. Clin. Pharmacol.,, 2024. [DOI]
  68. M. F. N. Meeran, F. Laham, S. Azimullah, C. Sharma, A. J. Al Kaabi, S. Tariq. β-Caryophyllene, a natural bicyclic sesquiterpene attenuates β-adrenergic agonist-induced myocardial injury in a cannabinoid receptor-2 dependent and independent manner.. Free Radic. Biol. Med., 2021. [DOI | PubMed]
  69. G. J. Molderings, J. Likungu, M. Göthert. Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship.. Naunyn Schmiedeb. Arch. Pharmacol., 1999. [DOI]
  70. F. Montecucco, S. Lenglet, V. Braunersreuther, F. Burger, G. Pelli, M. Bertolotto. CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion.. J. Mol. Cell. Cardiol., 2009. [DOI | PubMed]
  71. S. A. More, R. S. Deore, H. D. Pawar, C. Sharma, K. T. Nakhate, S. S. Rathod. CB2 cannabinoid receptor as a potential target in myocardial infarction: exploration of molecular pathogenesis and therapeutic strategies.. Int. J. Mol. Sci., 2024. [DOI | PubMed]
  72. C. E. Murry, R. B. Jennings, K. A. Reimer. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.. Circulation, 1986. [DOI | PubMed]
  73. P. Pacher, G. Haskó. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.. Br. J. Pharmacol., 2008. [DOI | PubMed]
  74. P. Pacher, S. Steffens, G. Haskó, T. H. Schindler, G. Kunos. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.. Nat. Rev. Cardiol., 2018. [DOI | PubMed]
  75. M. D. A. Paskeh, A. Asadi, S. Mirzaei, M. Hashemi, M. Entezari, R. Raesi. Targeting AMPK signaling in ischemic/reperfusion injury: from molecular mechanism to pharmacological interventions.. Cell. Signal., 2022. [DOI | PubMed]
  76. H. D. Pawar, U. B. Mahajan, K. T. Nakhate, Y. O. Agrawal, C. R. Patil, M. F. N. Meeran. Curcumin protects diabetic mice against isoproterenol-induced myocardial infarction by modulating CB2 cannabinoid receptors.. Life (Basel), 2022. [DOI | PubMed]
  77. C. Penna, S. Comità, F. Tullio, G. Alloatti, P. Pagliaro. Challenges facing the clinical translation of cardioprotection: 35 years after the discovery of ischemic preconditioning.. Vasc. Pharmacol., 2022. [DOI]
  78. S. L. Puhl. Cannabinoid-sensitive receptors in cardiac physiology and ischaemia.. Biochim. Biophys. Acta. Mol. Cell. Res., 2020. [DOI | PubMed]
  79. S. L. Puhl, M. Hilby, M. Kohlhaas, L. M. Keidel, Y. Jansen, M. Hristov. Haematopoietic and cardiac GPR55 synchronize post-myocardial infarction remodelling.. Sci. Rep., 2021. [DOI | PubMed]
  80. M. Rajesh, P. Mukhopadhyay, S. Bátkai, M. Arif, Z. V. Varga, C. Mátyás. Cannabinoid receptor 2 activation alleviates diabetes-induced cardiac dysfunction, inflammation, oxidative stress, and fibrosis.. Geroscience, 2022. [DOI | PubMed]
  81. M. Rajesh, P. Mukhopadhyay, G. Haskó, L. Liaudet, K. Mackie, P. Pacher. Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells.. Br. J. Pharmacol., 2010. [DOI | PubMed]
  82. S. Rajlic, L. Surmann, P. Zimmermann, C. K. Weisheit, L. Bindila, H. Treede. Fatty acid amide hydrolase deficiency is associated with deleterious cardiac effects after myocardial ischemia and reperfusion in mice.. Int. J. Mol. Sci., 2022. [DOI | PubMed]
  83. O. J. Robertson-Gray, S. K. Walsh, E. Ryberg, A. C. Jönsson-Rylander, C. Lipina, C. L. Wainwright. l-α-Lysophosphatidylinositol (LPI) aggravates myocardial ischemia/reperfusion injury via a GPR55/ROCK-dependent pathway.. Pharmacol. Res. Perspect., 2019. [DOI | PubMed]
  84. B. R. Rorabaugh, J. Guindon, D. J. Morgan. Role of cannabinoid signaling in cardiovascular function and ischemic injury.. J. Pharmacol. Exp. Ther., 2023. [DOI | PubMed]
  85. S. Roth, C. Torregroza, K. Feige, B. Preckel, M. W. Hollmann, N. C. Weber. Pharmacological conditioning of the heart: an update on experimental developments and clinical implications.. Int. J. Mol. Sci., 2021. [DOI | PubMed]
  86. M. Ruiz, L. Coderre, B. G. Allen, C. Des Rosiers. Protecting the heart through MK2 modulation, toward a role in diabetic cardiomyopathy and lipid metabolism.. Biochim. Biophys. Acta. Mol. Basis. Dis., 2018. [DOI | PubMed]
  87. M. J. Schloss, M. Horckmans, R. Guillamat-Prats, D. Hering, E. Lauer, S. Lenglet. 2-Arachidonoylglycerol mobilizes myeloid cells and worsens heart function after acute myocardial infarction.. Cardiovasc. Res., 2019. [DOI | PubMed]
  88. Y. A. Shmist, I. Goncharov, M. Eichler, V. Shneyvays, A. Isaac, Z. Vogel. Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production.. Mol. Cell. Biochem., 2006. [DOI | PubMed]
  89. S. Slavic, D. Lauer, M. Sommerfeld, U. R. Kemnitz, A. Grzesiak, M. Trappiel. Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome.. J. Mol. Med. Berl., 2013. [DOI | PubMed]
  90. R. Smoum, U. Grether, M. Karsak, A. J. Vernall, F. Park, C. J. Hillard. Editorial: therapeutic potential of the cannabinoid CB2 receptor.. Front. Pharmacol., 2022. [DOI | PubMed]
  91. S. Steffens, P. Pacher. Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies.. Br. J. Pharmacol., 2012. [DOI | PubMed]
  92. L. Sterin-Borda, C. F. Del Zar, E. Borda. Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways.. Biochem. Pharmacol., 2005. [DOI | PubMed]
  93. K. Sugamura, S. Sugiyama, T. Nozaki, Y. Matsuzawa, Y. Izumiya, K. Miyata. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages.. Circulation, 2009. [DOI | PubMed]
  94. H. J. Sun, Y. Lu, H. W. Wang, H. Zhang, S. R. Wang, W. Y. Xu. Activation of endocannabinoid receptor 2 as a mechanism of propofol pretreatment-induced cardioprotection against ischemia-reperfusion injury in rats.. Oxid. Med. Cell. Longev., 2017. [DOI | PubMed]
  95. M. Szekeres, G. L. Nádasy, E. Soltész-Katona, L. Hunyady. Control of myogenic tone and agonist induced contraction of intramural coronary resistance arterioles by cannabinoid type 1 receptors and endocannabinoids.. Prostagl. Other Lipid Mediat, 2018. [DOI]
  96. X. Tang, Z. Liu, X. Li, J. Wang, L. Li. Cannabinoid receptors in myocardial injury: a brother born to rival.. Int. J. Mol. Sci., 2021. [DOI | PubMed]
  97. M. Toczek, B. Malinowska. Enhanced endocannabinoid tone as a potential target of pharmacotherapy.. Life Sci., 2018. [DOI | PubMed]
  98. D. S. Ugdyzhekova, A. V. Krylatov, N. A. Bernatskaya, L. N. Maslov, R. Mechoulam, R. G. Pertwee. Activation of cannabinoid receptors decreases the area of ischemic myocardial necrosis.. Bull. Exp. Biol. Med., 2002. [DOI | PubMed]
  99. N. J. Underdown, C. R. Hiley, W. R. Ford. Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism.. Br. J. Pharmacol., 2005. [DOI | PubMed]
  100. I. Valenta, Z. V. Varga, H. Valentine, R. Cinar, A. Horti, W. B. Mathews. Feasibility evaluation of myocardial cannabinoid type 1 receptor imaging in obesity: a translational approach.. JACC Cardiovasc. Imaging., 2018. [DOI | PubMed]
  101. A. C. M. van Esbroeck, Z. V. Varga, X. Di, E. J. van Rooden, V. E. Tóth, Z. Onódi. Activity-based protein profiling of the human failing ischemic heart reveals alterations in hydrolase activities involving the endocannabinoid system.. Pharmacol. Res., 2020. [DOI | PubMed]
  102. J. A. Wagner, M. Abesser, J. Harvey-White, G. Ertl. 2-Arachidonylglycerol acting on CB1 cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts.. J. Cardiovasc. Pharmacol., 2006. [DOI | PubMed]
  103. J. A. Wagner, K. Hu, J. Karcher, J. Bauersachs, A. Schäfer, M. Laser. CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction.. Br. J. Pharmacol., 2003. [DOI | PubMed]
  104. M. Waldman, E. Hochhauser, M. Fishbein, D. Aravot, A. Shainberg, Y. Sarne. An ultra-low dose of tetrahydrocannabinol provides cardioprotection.. Biochem. Pharmacol., 2013. [DOI | PubMed]
  105. S. K. Walsh, C. Y. Hepburn, K. A. Kane, C. L. Wainwright. Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion.. Br. J. Pharmacol., 2010. [DOI | PubMed]
  106. P. F. Wang, L. S. Jiang, J. Bu, X. J. Huang, W. Song, Y. P. Du. Cannabinoid-2 receptor activation protects against infarct and ischemia-reperfusion heart injury.. J. Cardiovasc. Pharmacol., 2012. [DOI | PubMed]
  107. Q. Wang, C. J. Zuurbier, R. Huhn, C. Torregroza, M. W. Hollmann, B. Preckel. Pharmacological cardioprotection against ischemia reperfusion injury-the search for a clinical effective therapy.. Cells, 2023. [DOI | PubMed]
  108. Y. Wang, S. Ma, Q. Wang, W. Hu, D. Wang, X. Li. Effects of cannabinoid receptor type 2 on endogenous myocardial regeneration by activating cardiac progenitor cells in mouse infarcted heart.. Sci. China Life Sci., 2014. [DOI | PubMed]
  109. F. Weis, A. Beiras-Fernandez, R. Sodian, I. Kaczmarek, B. Reichart, A. Beiras. Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure.. J. Mol. Cell. Cardiol., 2010. [DOI | PubMed]
  110. J. Weresa, A. Pędzińska-Betiuk, K. Mińczuk, B. Malinowska, E. Schlicker. Why do marijuana and synthetic cannabimimetics induce acute myocardial infarction in healthy young people?. Cells, 2022. [DOI | PubMed]
  111. Z. M. Whiting, J. Yin, S. M. de la Harpe, A. J. Vernall, N. L. Grimsey. Developing the cannabinoid receptor 2 (CB2) pharmacopoeia: past, present, and future.. Trends Pharmacol. Sci., 2022. [DOI | PubMed]
  112. J. D. Yu, S. Miyamoto. Molecular signaling to preserve mitochondrial integrity against ischemic stress in the heart: rescue or remove mitochondria in danger.. Cells, 2021. [DOI | PubMed]
  113. W. Yu, G. Jin, J. Zhang, W. Wei. Selective activation of cannabinoid receptor 2 attenuates myocardial infarction via suppressing NLRP3 inflammasome.. Inflammation, 2019. [DOI | PubMed]
  114. Y. F. Zeng, Q. H. Guo, X. Y. Wei, S. Y. Chen, S. Deng, J. J. Liu. Cardioprotective effect of curcumin on myocardial ischemia/reperfusion injury: a meta-analysis of preclinical animal studies.. Front. Pharmacol., 2023. [DOI | PubMed]
  115. W. Zhao, D. J. Hausenloy, D. C. Hess, D. M. Yellon, X. Ji. Remote ischemic conditioning: challenges and opportunities.. Stroke, 2023. [DOI | PubMed]

Related Posts

The content on this platform is provided for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any health-related decisions.